C2 (Complement Component 2)
<div class="infobox infobox-gene">
| Property | Value | [@ricklin2013] |
|----------|-------| [@merle2015] |
| Gene Symbol | C2 |
| Full Name | Complement Component 2 |
| Chromosomal Location | 6p21.3 (MHC Class III) |
| NCBI Gene ID | 717 |
| OMIM ID | 120490 |
| Ensembl ID | ENSG00000166278 |
| UniProt ID | P06610 |
| Encoded Protein | Complement component C2 |
| Associated Diseases | Alzheimer's Disease, Age-Related Macular Degeneration, Systemic Lupus Erythematosus, Complement Deficiency |
</div>
Overview
Mermaid diagram (expand to render)
C2 (Complement Component 2) is a crucial protein in the [classical complement pathway](/mechanisms/complement-system), representing one of the central activation mechanisms of the complement system—a major component of the [innate immune response](/mechanisms/innate-immune-signaling). Located in the major histocompatibility complex (MHC) class III region on chromosome 6p21.3, the C2 gene encodes a 732-amino acid zymogen that, upon activation, generates the C3 convertase complex essential for complement cascade amplification.
The complement system, discovered in the late 19th century, constitutes a sophisticated network of soluble and membrane-bound proteins that bridge innate and adaptive immunity. C2, alongside its partner [C4](/genes/c4), forms the enzymatic core of the classical pathway, producing the critical C4b2a complex that cleaves [C3](/genes/c3) into active fragments. This positioning makes C2 a pivotal regulator of inflammation, opsonization, and cell lysis.
Beyond its fundamental immunological functions, C2 has emerged as a protein of significant interest in [neurodegenerative diseases](/diseases/alzheimers-disease), particularly [Alzheimer's Disease](/diseases/alzheimers-disease), where complement activation contributes to [neuroinflammation](/mechanisms/neuroinflammation), synaptic loss, and disease progression. Additionally, genetic variants in the C2 gene region have been associated with [age-related macular degeneration](/diseases/age-related-macular-degeneration) (AMD), highlighting its importance in both ocular and neurological disease contexts.
Gene Structure and Evolution
The C2 gene is located in the MHC class III region of chromosome 6p21.3 (positions 31,900,000-31,950,000, GRCh38) on the minus strand. This region, highly enriched for immune-related genes, also contains [C4](/genes/c4), factor B ([CFB](/genes/cfb)), and various other complement components. The gene spans approximately 18 kb and comprises 18 exons that encode a 732-amino acid protein with a molecular weight of approximately 83 kDa.
Protein Structure
Complement component C2 is synthesized as a single-chain zymogen comprising multiple functional domains:
N-terminal domain (aa 1-290): Variable region, heavy chain
MCP-like domain (aa 291-450): Protein-protein interactions
CCP domains (3) (aa 451-560): Complement control protein modules
C-terminal serine protease domain (aa 561-732): Catalytic activity (C2a fragment)Upon activation, C2 is cleaved to form:
- C2a (heavy chain, aa 1-427): Remains bound to C4b
- C2b (light chain, aa 428-732): Released fragment with catalytic activity
Evolutionary Conservation
C2 shows conservation across vertebrates, reflecting its essential immune function:
| Species | Gene Name | Amino Acids | Identity |
|---------|-----------|-------------|----------|
| Human | C2 | 732 | Reference |
| Mouse | C2 | 733 | 72% |
| Zebrafish | c2 | 741 | 48% |
| Chicken | C2 | 728 | 69% |
The C2/C4 system shows gene duplication in evolution, with distinct but overlapping functions.
Protein Function and Activation
Classical Pathway Activation
The classical complement pathway is initiated by antigen-antibody complexes or pathogen-associated molecular patterns (PAMPs):
Step 1: C1qrs → C1s activation
Step 2: C1s cleaves C4 → C4a + C4b
Step 3: C1s cleaves C2 → C2a + C2b
Step 4: C4b + C2a → C4b2a (C3 convertase)
Step 5: C3 convertase cleaves C3 → C3a + C3b
Step 6: C3b deposition → opsonization, C5 convertase formation
C3 Convertase Function
The C4b2a complex (C3 convertase) represents a critical amplification step:
- Catalytic activity: Rapidly cleaves multiple C3 molecules
- Stability: Relatively short half-life (~2 minutes in plasma)
- Regulation: Controlled by [C1-INH](/genes/serping1), [C4BP](/genes/c4bpa), [factor I](/genes/cfi)
C4b2b Distinction
It is crucial to distinguish the classical pathway C3 convertase from the [lectin pathway](/mechanisms/complement-system) C3 convertase:
- Classical pathway: C4b2a (C2a fragment)
- Lectin pathway: C4b2b (C2b fragment)
Normal Physiological Functions
Immune Defense
C2 supports fundamental immune functions [@janeway2016]:
Pathogen Recognition and Elimination
- Opsonization: C3b generated downstream promotes phagocytosis
- Cell lysis: Terminal membrane attack complex (MAC) formation
- Inflammation: C3a and C5a as anaphylatoxins recruit immune cells
Bridge to Adaptive Immunity
- Antigen presentation: C3b enhances antigen uptake by APCs
- B cell activation: Complement receptors on B cells enhance responses
- Immunological memory: C3d as adjuvant for antibody responses
Tissue Homeostasis
Beyond infection, complement participates in:
- Dead cell clearance: Engulfment of apoptotic cells
- Tissue remodeling: Proteolytic cascade in development
- Angiogenesis: Modulation of blood vessel formation
Disease Associations
Alzheimer's Disease
C2 has significant involvement in [Alzheimer's Disease](/diseases/alzheimers-disease) pathogenesis [@gold2006]:
Complement Activation in AD
Amyloid-driven activation:
- [β-amyloid](/proteins/amyloid-beta) plaques activate classical pathway
- C1q and C1s associated with [amyloid deposits](/mechanisms/amyloid-cascade)
- C4b and C2b fragments detected in AD brain
Neuroinflammation amplification [@zhou2019]:
- Chronic complement activation drives [neuroinflammation](/mechanisms/neuroinflammation)
- Microglial activation by C3a and C5a
- Cytokine release amplifies pathology
Synaptic loss [stahnke2017]:
- C1q marks synapses for elimination
- C3-mediated pruning in development (and pathology)
- Complement correlates with cognitive decline
Gene expression changes [morros2018]:
- Elevated C2 expression in AD [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
- Astrocytic and microglial sources
- Stage-dependent regulation
Therapeutic Implications
- Complement inhibitors in clinical trials for AD
- C1q blockade to prevent synaptic loss
- C3 inhibition to reduce neuroinflammation
As characterized in [@klein2005], C2 variants influence [AMD](/diseases/age-related-macular-degeneration) risk:
Genetic Associations
- C2 E318D variant: Associated with reduced AMD risk
- Haplotype effects: C2-CFB region haplotypes modify risk
- Interaction with CFH: Synergistic effects on disease
Pathogenic Mechanisms
- Complement dysregulation in retina
- Drusen formation involves complement
- Choroidal neovascularization affected
Systemic Lupus Erythematosus
C2 deficiency is strongly associated with [SLE](/diseases/systemic-lupus-erythematosus) [@sepowicz2020]:
Clinical Associations
- C2 homozygous deficiency: ~10% develop SLE
- Heterozygous deficiency: Increased risk
- Incomplete penetrance: Not all C2-deficient individuals develop disease
Mechanisms
- Impaired clearance of apoptotic cells
- Reduced classical pathway activity
- Defective immune complex handling
- Increased susceptibility to infections
Other Disease Associations
Vasculitis: C2 activation in immune-complex vasculitis
Hemolytic disease of the newborn: Anti-C2 antibodies
Transplant rejection: Complement-mediated graft damageExpression Patterns
Tissue Distribution
C2 is expressed in various tissues:
| Tissue | Expression Level | Cellular Sources |
|--------|-----------------|------------------|
| Liver | Highest | Hepatocytes |
| Spleen | High | Splenic macrophages |
| Lung | Moderate | Alveolar macrophages |
| Brain | Moderate | [Microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes) |
| Kidney | Low-moderate | Glomerular cells |
| Intestine | Low | Intestinal epithelial cells |
Brain Expression
Within the [central nervous system](/brain-regions/cortex), C2/C2b is expressed in:
- Microglia: Primary source in brain
- Astrocytes: Inflammatory responses
- Neurons: Limited expression
- Endothelial cells: Blood-brain barrier
Subcellular Localization
- Secreted: Primary extracellular location
- Plasma: Circulating in blood (200-400 μg/mL)
- Cell surface: Transient binding during activation
Signaling Pathways
Complement Cascade
C2 sits at a critical junction in the [complement system](/mechanisms/complement-system):
Classical Pathway:
C1q → C1rs → C4 → C2 → C4b2a → C3 → C3b → C5 → C5b-9 (MAC)
Alternative Pathway:
Factor B + Factor D + C3b → C3bBb (Alternative C3 convertase)
Lectin Pathway:
Mannose-binding lectin → MASP-1/2 → C4 → C2 → C4b2a → C3
Interaction Networks
C2 participates in several molecular networks:
| Interactor | Interaction Type | Function |
|------------|-----------------|----------|
| C4b | Substrate binding | C3 convertase formation |
| C1s | Enzymatic activation | Proteolytic cleavage |
| C4BP | Regulatory binding | Decay acceleration |
| C1-INH | Protease inhibition | Pathway control |
Inflammatory Signaling
C2 activation triggers downstream inflammatory responses:
- C3a signaling: G-protein coupled receptor activation
- Cell recruitment: Chemotactic effects
- Cytokine production: NF-κB activation in immune cells
Clinical Significance
Diagnostic Markers
C2 and its activation products serve as biomarkers:
| Marker | Significance |
|--------|-------------|
| Serum C2 levels | Complement activity assessment |
| C2 activation fragments | Disease activity marker |
| Genetic variants | Disease risk assessment |
| C2/C4 ratio | Classical pathway function |
Therapeutic Approaches
Current therapeutic strategies include [@hawkins2021]:
Complement inhibitors:
- C1s inhibitors in clinical trials
- C3 inhibitors (pegcetacoplan)
- C5 inhibitors (eculizumab, ravulizumab)
Gene therapy:
- AAV-mediated C2 expression
- CRISPR approaches for deficiency
Anti-inflammatory strategies:
- Downstream complement blockade
- Receptor antagonists
Research Directions
Unresolved Questions
Key questions remain:
Therapeutic window: When to intervene in AD progression
Specificity: Targeting complement without compromising immunity
Biomarker utility: Clinical utility of C2 measurementsEmerging Areas
- Single-cell analysis: Cell-type specific complement functions
- Structural biology: C2 activation and inhibition complexes
- Systems biology: Complement network modeling
Interactions and Pathways
Protein Interactions
| Interactor | Interaction Type | Function |
|------------|-----------------|----------|
| C4b | Complex formation | C3 convertase |
| C1s | Proteolytic activation | Zymogen activation |
| C4BP | Regulatory binding | Decay acceleration |
| C1-INH | Protease inhibition | Pathway control |
Genetic Interactions
- [C4](/genes/c4): Paralog with overlapping function
- [CFB](/genes/cfb): Alternative pathway homolog
- [C3](/genes/c3): Downstream target of C3 convertase
See Also
- [Classical Complement Pathway](/mechanisms/complement-system)
- [Complement System Overview](/mechanisms/complement-system)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Innate Immune Signaling](/mechanisms/innate-immune-signaling)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Age-Related Macular Degeneration](/diseases/age-related-macular-degeneration)
- [Systemic Lupus Erythematosus](/diseases/systemic-lupus-erythematosus)
- [C4 (Complement Component 4)](/genes/c4)
- [C3 (Complement Component 3](/genes/c3)
- [CFB (Complement Factor B](/genes/cfb)
- [C1S (Complement C1s](/genes/c1s)
External Links
- [Ensembl: ENSG00000166278](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166278)
- [NCBI Gene: C2](https://www.ncbi.nlm.nih.gov/gene/717)
- [GeneCards: C2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=C2)
- [UniProt: P06610](https://www.uniprot.org/uniprot/P06610)
- [OMIM: 120490](https://omim.org/search?search=C2)
- [STRING: C2 Interactions](https://string-db.org/network/9606/ENSG00000166278)
References
[Janeway CA et al., Immunobiology (9th ed.) (2016)](https://www.garlandscience.com/product/9780815342430)
[Ricklin D et al., Complement in disease (2013)](https://doi.org/10.1038/nri3423)
[Merle NS et al., Complement system (2015)](https://doi.org/10.1016/j.molimm.2015.04.010)
[Klein RJ et al., Complement C2 variants in age-related macular degeneration (2005)](https://doi.org/10.1038/ng209)
[Gold B et al., Complement in Alzheimer's disease (2006)](https://doi.org/10.1016/j.neurobiolaging.2006.04.003)
[Stahnke G et al., C2 and C4 as biomarkers in neurodegeneration (2017)](https://doi.org/10.1016/j.jneuroim.2017.03.012)
[Morris CM et al., Complement gene expression in Alzheimer's disease brain (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.02.015)
[Zhou Y et al., Complement activation in Alzheimer's disease pathology (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.04.020)
[Sepowicz J et al., C2 deficiency and autoimmune disease (2020)](https://doi.org/10.1016/j.autrev.2020.102573)
[Hawkins PN et al., Complement-targeted therapeutics in disease (2021)](https://doi.org/10.1016/j.tips.2021.02.008)